DAPAKAN

Epilepsy: Dapakan is indicated for use as sole and adjunctive therapy in the treatment of simple (petit mal) and complex absence seizures, as well as in generalized tonic clonic (grand mal) juvenile myoclonic and partial (focal, local) simple / complex seizures. In accordance with the international classification of seizures, simple absence is defined as very brief clouding of the sensorium or loss of consciousness (lasting usually 2 - 15 seconds), accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present.

Mania: Dapakan tablets are indicated for the treatment of the manic episodes associated with bipolar disorder. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech motor hyperactivity reduced need for sleep, flight of ideas, grandiosity, poor judgment, aggressiveness, and possible hostility.
The safety effectiveness of Dapakan for long term use in mania, i.e. more than three weeks, has not been systematically evaluated in controlled clinical trials. Therefore physicians who elect to use Dapakan for extended periods should continually reevaluate the long-term usefulness of the drugs for the individual patient

Migraine: Dapakan tablets are indicated for prophylaxis of migraine headaches. There is no evidence that Dapakan is useful in the acute
treatment of migraine headaches. Because valproic acid may be a hazard to the fetus. Dapakan should be considered for women of childbearing potential only after risk has been thoroughly discussed with the patient and weighted against the potential benefits of treatment (See WARNINGS-Usage in Pregnancy).